Combinations with FLT3 inhibitors: the way forward for AML treatment
Can we cure 50% of all multiple myeloma patients in the next five years?
The prognostic value of IDH1 and IDH2 in acute myeloid leukemia (AML)
Panobinostat and donor lymphocyte infusions in patients with high-risk AML and MDS
Predict response to immune checkpoint inhibition in acute myeloid leukemia (AML) using biomarkers
Naval G. Daver